A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR monoclonal antibody therapy Versus the Reverse Sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan (REVERCE II)
Categories (click each to see list of all clinical trials associated with that category): GI (ONC)
Current Status: Open
Phase: II (Cancer Control)
Principal Investigator: Klute, Kelsey
Contact Information:
Brandie Booker, RN
402-559-8197
brandie.booker@unmc.edu
Eligibility: https://clinicaltrials.gov/search?term=NCT04117945&rank=1
Summary